These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 7072415)

  • 21. [Pathogenesis and pathophysiology of myasthenia gravis--the role of thymus in myasthenia gravis (author's transl)].
    Ohshima F
    No To Shinkei; 1980 Sep; 32(9):909-19. PubMed ID: 7437164
    [No Abstract]   [Full Text] [Related]  

  • 22. The effect of myasthenic thymus fragments transplantation on the immune state of patients with proliferative and aplastic diseases of the haematopoetic system.
    Szmigiel Z; Turowski G; Rzepecki WM; Aleksandrowicz J; Skotnicki AB
    Acta Med Pol; 1975; 16(2):61-82. PubMed ID: 1146608
    [No Abstract]   [Full Text] [Related]  

  • 23. [Therapeutic strategy in myasthenia gravis].
    Tranchant C
    Rev Neurol (Paris); 2009 Feb; 165(2):149-54. PubMed ID: 19233080
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis.
    Evoli A; Tonali PA; Padua L; Monaco ML; Scuderi F; Batocchi AP; Marino M; Bartoccioni E
    Brain; 2003 Oct; 126(Pt 10):2304-11. PubMed ID: 12821509
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic plasma exchange in patients with neurologic diseases: retrospective multicenter study.
    Kaynar L; Altuntas F; Aydogdu I; Turgut B; Kocyigit I; Hacioglu SK; Ismailogullari S; Turgut N; Erkurt MA; Sari I; Oztekin M; Solmaz M; Eser B; Ersoy AO; Unal A; Cetin M
    Transfus Apher Sci; 2008 Apr; 38(2):109-15. PubMed ID: 18331814
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Myasthenia gravis: effect of immunoactive therapies.
    Fornádi L; Horváth R; Bárdosi Z; Szobor A
    Acta Med Hung; 1994; 50(1-2):83-92. PubMed ID: 7638045
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Langerhans cell histiocytosis associated with myasthenia in an infant].
    Bertrand Y; Dutour A; Manel AM; Souillet G; Philippe N
    Pediatrie; 1993; 48(11):780-2. PubMed ID: 8058436
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interferon causes no myasthenia in a seropositive patient with multiple sclerosis.
    Shimizu H; Kataoka H; Kawahara M; Hirano M; Furiya Y; Ueno S
    Clin Neurol Neurosurg; 2007 Apr; 109(3):277-8. PubMed ID: 17118531
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Contrasting defects of T-lymphocyte mitogenic response in multiple sclerosis and myasthenia gravis.
    Richman DP; Dropcho EJ; Antel JP; Arnason BG
    Trans Am Neurol Assoc; 1978; 103():191-3. PubMed ID: 316215
    [No Abstract]   [Full Text] [Related]  

  • 30. Autoimmune diseases against cell surface receptors: myasthenia gravis, a prototype anti-receptor disease.
    De Baets MH
    Neth J Med; 1994 Dec; 45(6):294-301. PubMed ID: 7838246
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Usefulness of plasmapheresis before thymectomy in the management of myasthenia gravis].
    Iváñez V; Díez-Tejedor E; Lara M; Barreiro P
    Neurologia; 1994; 9(7):277-81. PubMed ID: 7946422
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Myasthenia-multiple sclerosis: a possible pathogenetic relationship?].
    De Meyer F; Maquet JC; Gyselings R
    Rev Med Brux; 1988 Sep; 9(6):321-5. PubMed ID: 3051249
    [No Abstract]   [Full Text] [Related]  

  • 33. Altered populations of natural killer cell and natural killer T cell subclasses in myasthenia gravis.
    Suzuki Y; Onodera H; Tago H; Saito R; Ohuchi M; Shimizu M; Itoyama Y
    J Neuroimmunol; 2005 Oct; 167(1-2):186-9. PubMed ID: 16040133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Distribution of B-lymphocyte subgroup CD20 and its clinical significance in patients with myasthenia gravis].
    Zhang Q; Hu Y; Zhang L; Li Y; Yin H; Li J
    Zhonghua Wai Ke Za Zhi; 1998 Apr; 36(4):239-41. PubMed ID: 11825378
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased mast cell density and microvessel density in the thymus of patients with myasthenia gravis.
    Raica M; Cîmpean AM; Encică S; Scridon T; Bârsan M
    Rom J Morphol Embryol; 2007; 48(1):11-6. PubMed ID: 17502945
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Suppressor cell function in multiple sclerosis.
    Arnason BG; Antel J
    Ann Immunol (Paris); 1978; 129(2-3):159-70. PubMed ID: 677810
    [No Abstract]   [Full Text] [Related]  

  • 37. Thymus and Myasthenia Gravis: what can we learn from DNA microarrays?
    Cizeron-Clairac G; Le Panse R; Frenkian-Cuvelier M; Meraouna A; Truffault F; Bismuth J; Mussot S; Kerlero de Rosbo N; Berrih-Aknin S
    J Neuroimmunol; 2008 Sep; 201-202():57-63. PubMed ID: 18691767
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Diagnosis of thymoma and thymic atrophy in patients with myasthenia gravis].
    Sund KK; Skeie GO; Gilhus NE; Aarli JA; Varhaug JE
    Tidsskr Nor Laegeforen; 1997 Nov; 117(29):4212-4. PubMed ID: 9441462
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Altered intrathymic T-cell repertoire in human myasthenia gravis.
    Truffault F; Cohen-Kaminsky S; Khalil I; Levasseur P; Berrih-Aknin S
    Ann Neurol; 1997 Jun; 41(6):731-41. PubMed ID: 9189034
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Organ-specific autoantigens induce transforming growth factor-beta mRNA expression in mononuclear cells in multiple sclerosis and myasthenia gravis.
    Link J; Fredrikson S; Söderström M; Olsson T; Höjeberg B; Ljungdahl A; Link H
    Ann Neurol; 1994 Feb; 35(2):197-203. PubMed ID: 7509140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.